Natixis Advisors LLC Grows Stock Position in argenx SE (NASDAQ:ARGX)

Natixis Advisors LLC raised its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 32.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,923 shares of the company's stock after purchasing an additional 3,909 shares during the period. Natixis Advisors LLC's holdings in argenx were worth $9,793,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Whipplewood Advisors LLC bought a new stake in shares of argenx in the 4th quarter valued at $37,000. Global Retirement Partners LLC lifted its holdings in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares during the period. Jones Financial Companies Lllp lifted its holdings in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares during the period. Farther Finance Advisors LLC boosted its position in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after acquiring an additional 21 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in argenx during the 4th quarter worth about $66,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Performance

NASDAQ ARGX traded down $2.43 during trading hours on Tuesday, hitting $605.52. The company had a trading volume of 161,915 shares, compared to its average volume of 282,872. The firm has a market capitalization of $36.79 billion, a price-to-earnings ratio of -688.09 and a beta of 0.59. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The firm has a 50 day simple moving average of $633.44 and a 200 day simple moving average of $600.67.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, research analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ARGX shares. Wedbush reiterated an "outperform" rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. Wells Fargo & Company lifted their price objective on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Robert W. Baird increased their target price on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Oppenheimer lifted their price target on shares of argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Finally, Citigroup reissued an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, argenx presently has a consensus rating of "Moderate Buy" and a consensus price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.